Velocity Clinical Research Germany GmbH

At Velocity Clinical Research Germany GmbH investigators are exploring innovative treatments aimed at reducing heart‑related events and improving cholesterol management. Studies focus on patients with heart failure, atherosclerotic disease, and high LDL‑cholesterol, seeking to demonstrate superior outcomes over existing standards.

• Combination therapy with a novel agent and empagliflozin for heart failure
• Fixed‑dose combination of laroprovstat and rosuvastatin to lower LDL‑C
• Evaluation of AZD0780 for reducing major adverse cardiovascular events

These trials aim to test new therapeutic options that could lower mortality and hospitalizations in cardiovascular patients.

Research at the site includes a study of a probiotic formulation designed to alleviate symptoms of diarrhoea‑predominant irritable bowel syndrome, assessing both efficacy and safety compared with placebo.

• Oral probiotic therapy for IBS‑D symptom reduction

The goal is to provide patients with an effective, non‑antibiotic option for managing this chronic condition.

Investigators are conducting vaccine trials that target seasonal influenza and SARS‑CoV‑2, evaluating immune responses in older adults to ensure protective efficacy.

• Influenza vaccine efficacy in adults aged 65 and older
• Combination COVID‑19 and influenza vaccine immunogenicity

These studies seek to confirm that the vaccines generate strong, lasting immunity without compromising safety.

A clinical program is assessing the pain‑relieving potential of a medical‑cannabis aerosol for individuals suffering from diabetic peripheral neuropathic pain.

• Medical cannabis aerosol for neuropathic pain management

The trial evaluates whether this inhaled formulation can significantly lower pain intensity compared with placebo.

The center is evaluating therapies aimed at weight reduction and kidney health, including a novel agent for obesity without diabetes and a drug that may slow renal decline in chronic kidney disease.

• Weight‑loss intervention for obesity and overweight with comorbidities
• Renal outcome study in chronic kidney disease patients

These projects aim to improve metabolic parameters and preserve kidney function in at‑risk populations.

Trials focusing on viral infections evaluate the safety and reactogenicity of pandemic‑relevant vaccines, including a high‑dose influenza vaccine for seniors.

• Safety assessment of high‑dose influenza vaccine in adults ≥65 years

The objective is to confirm that the vaccine is well tolerated while providing robust protection against influenza viruses.

A study investigates the impact of an herbal preparation on depressive symptoms in patients with mild to moderate major depressive disorder.

• Silexan efficacy on depressive symptom reduction

The research aims to determine whether this treatment can meaningfully improve mood scores compared with placebo.